Chiral Cationic Lipid DOTAP Enantiomers for Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face challenges in effectively delivering antigens to antigen-presenting cells and stimulating robust immune responses, particularly for weakly immunogenic antigens, as existing adjuvants like MF59 primarily enhance antibody production rather than cell-mediated immunity and may not induce sufficient tumor regression.
Innovation Solution
The use of R and S enantiomers of cationic lipids, such as DOTAP, to form complexes with antigens, which act as potent immune activators by effectively delivering antigens to dendritic cells and inducing specific immune responses, including tumor regression at optimal dose ranges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional adjuvants like MF59 are used, then antibody production is enhanced, but cell-mediated immunity is not sufficiently stimulated
Solution Approach 1:
The patent changes the chemical structure parameter of the adjuvant by using cationic lipids with specific charge densities and compositions (e.g., DOTAP, DOGS) instead of traditional emulsion-based adjuvants. This parameter change enables the adjuvant to directly activate dendritic cells and stimulate cell-mediated immunity while maintaining antigen delivery capabilities
Solution Approach 2:
The patent creates composite structures by forming complexes between cationic lipids and antigens, where the cationic lipid component provides immunostimulatory activity and the antigen provides specificity. This composite approach allows simultaneous enhancement of both antibody production and cell-mediated immunity
2Reliability
If antigens are delivered to antigen-presenting cells, then immune response is stimulated, but delivery efficiency is insufficient for weakly immunogenic antigens
Solution Approach 1:
The patent uses cationic lipids as intermediary carriers that mediate between the antigen and the antigen-presenting cells. These lipid carriers facilitate efficient delivery of weakly immunogenic antigens to dendritic cells through electrostatic interactions and cellular uptake mechanisms, thereby enhancing immune response stimulation
Solution Approach 2:
The patent modifies the physical-chemical parameters of antigen delivery by using cationic lipids with specific charge densities, hydrophobicity, and molecular weights. These parameter optimizations enhance the delivery efficiency of antigens to antigen-presenting cells, particularly for weakly immunogenic antigens that would otherwise fail to elicit adequate immune responses
3Reliability
If R enantiomer of DOTAP is used, then strong immune activation and tumor regression are achieved, but if S enantiomer is used, then efficacy is limited
Solution Approach 1:
The patent applies asymmetry by specifically using the R-enantiomer of DOTAP, which has been shown to provide superior immune activation and tumor regression compared to the S-enantiomer. This chiral selection optimizes the immunostimulatory capability of the cationic lipid while maintaining ease of manufacture through available enantiomer separation techniques
Data Source
AI summary
A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R1 is a quaternary ammonium group, Y1 is a space chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combination thereof.